Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1

Pfizer partners with Blackstone for up to $1.5 billion in funding for obesity drug berobenatide. Payments depend on U.S. regulatory approval and sales milestones. Pfizer aims to advance its obesity program while maintaining financial flexibility for other investments.

Pfizer and Blackstone Life Sciences agreed on a $1.5bn co-funding deal for berobenatide, a potential first-in-class GLP-1 receptor agonist for chronic weight management. Pfizer will advance 20+ trials in 2026. Blackstone may receive milestone payments if berobenatide gains US approval and hits sales targets, but retains no ownership rights.

Pfizer and Blackstone Life Sciences agreed on a US$1.5bn deal to fund development of Pfizer's experimental obesity drug berobenatide through 2028. Blackstone will cover costs and receive milestone payments. Pfizer aims to strengthen its position in the GLP-1 obesity market, following its US$10bn acquisition of Metsera. Berobenatide showed 16% weight loss in Phase 2b trials. Blackstone has similar partnerships with Teva, Moderna, and Merck.

Pfizer (PFE) and Blackstone Life Sciences agreed to co-fund development of berobenatide, a GLP-1 obesity treatment. Blackstone will contribute up to $1.5B through 2028 and receive milestone payments upon regulatory and commercial success.

Blackstone Life Sciences will invest up to $1.5B in Pfizer's GLP-1 drug berobenatide for weight loss and type 2 diabetes. The funds will support 10 phase 3 trials. Pfizer acquired the drug via its $10B takeover of Metsera. Data shows significant weight loss and blood glucose control improvements.

Pfizer secured $1.5 billion from Blackstone to develop berobenatide, an obesity drug acquired via Metsera. Funding runs through 2028, with milestone payments but no equity stake for Blackstone, per Pfizer's press release.